Clinical trials: MDMA ('Ecstasy')
Posttraumatic Stress Disorder
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)
The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD).
- Trial name
- PAM-VET (NCT06989957)
- Testing
- Psilocybin, MDMA
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Autism Spectrum Disorder
Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls
This study is to investigate the physiological mechanism of oxytocin system stimulation using 3,4-methylenedioxymethamphetamine (MDMA) as a physiological tool (acute oxytocin releases), not as a medication.
- Trial name
- OxySPECTRUM (NCT07555132)
- Testing
- MDMA
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Amphetamine-Related Disorders
Functional Brain Imaging in Recreational Users of Ecstasy
Recreational use of "ecstasy" (MDMA; 3,4-methylenedioxymethamphetamine) is associated with long-lasting effects on metabolism in the human brain.
- Trial name
- NCT00254306
- Where
- Israel
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
PTSD
Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
- Trial name
- NCT04030169
- Testing
- Midomafetamine HCl
- Where
- 6 sites in Czechia, Germany and 3 more
- Volunteers
- 21 people
- Sponsor
- MAPS Europe B.V.
Posttraumatic Stress Disorder
Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder
This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment.
- Trial name
- NCT00353938
- Testing
- 3,4-methylenedioxymethamphetamine (125 mg), 3,4-methyelendioxymethamphetamine (25 mg), Therapy
- Where
- Switzerland
- Volunteers
- 14 people
- Sponsor
- Resilient Pharmaceuticals
Healthy
Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction
Serotonin and oxytocin play a role in fear conditioning and fear extinction learning, psychological processes that are critically involved in psychiatric disorders such as posttraumatic stress disorder (PTSD).
- Trial name
- MFE (NCT03527316)
- Testing
- MDMA
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Mood Disorder, Substance-Related Disorders
Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)
The purpose of this study is to determinate the effect of a pre-treatment with centrally acting alpha2-receptor agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA…
- Conditions
- Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders
- Trial name
- NCT01136278
- Testing
- 3,4-Methylenedioxymethamphetamine, Clonidine
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Posttraumatic Stress Disorder
Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD
The goal of this observational sub-study is to provide information on how MDMA-assisted therapy affects the brain and body of people with chronic PTSD.
- Trial name
- NCT02102802
- Testing
- Midomafetamine, Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Resilient Pharmaceuticals
Healthy
Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose
3,4-methylenedioxymethamphetamine (MDMA) is a psychoactive substance and prototypical empathogen acutely inducing feelings of heightened mood, empathy, trust and closeness to others.
- Trial name
- NCT05809271
- Testing
- MDMA 120 mg + MDMA 60 mg
- Where
- Switzerland
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Ecstasy (Drug), N-Methyl-3,4-Methylenedioxymethamphetamine
The NeXT Study; The Netherlands XTC Toxicity Study
The purpose of this study is to investigate the possible neurotoxic effects of the party-drug Ecstasy (MDMA)on brain and brain function in humans.
- Conditions
- Ecstasy (Drug), N-Methyl-3,4-Methylenedioxymethamphetamine, Psychopathology
- Trial name
- NCT00235768
- Where
- 3 sites in Netherlands
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Startle Response
Evaluation of MDMA on Startle Response
The goal of this clinical trial is to learn if MDMA impacts startle response in healthy participants. The main question it aims to answer is: Does MDMA impact participant's performance on a startle test? Researchers will compare…
- Trial name
- NCT03181763
- Testing
- Midomafetamine, Acoustic startle
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Resilient Pharmaceuticals
Anxiety Disorder, Cancer
MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer
This is a pilot study intended to find out if 3,4-methylenedioxymethamphetamine (MDMA) is safe and can help people with advanced stage cancer and anxiety arising from the cancer diagnosis.
- Trial name
- NCT00252174
- Testing
- Stage 1 Active Methylenedioxymethamphetamine, Stage 1 Low dose Methylenedioxymethamphetamine, Psychotherapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brigham and Women's Hospital
Mood Disorder, Substance-Related Disorders
Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)
The purpose of this study is to determinate the effect of a pre-treatment with carvedilol, a alpha- and beta-adrenergic receptor blocker, on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA…
- Conditions
- Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders
- Trial name
- NCT01270672
- Testing
- 3,4-Methylenedioxymethamphetamine, carvedilol
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Diabetes Insipidus
Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls
This study is to evaluate oxytocin levels in response to MDMA administration as compared to placebo in patients with diabetes insipidus and healthy volunteers.
- Trial name
- OxyMA (NCT04648137)
- Testing
- study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Mood Disorder, Substance-Related Disorders
Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)
The purpose of this study is to determinate the effect of a pre-treatment with doxazosin, a alpha1-adrenergic receptor blocker, on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
- Conditions
- Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders
- Trial name
- NCT01386177
- Testing
- 3,4-Methylenedioxymethamphetamine, Doxazosin
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Depressive Disorder, Major, Bipolar Disorder
Characterization of the Prosocial and Prosexual Effects of GHB
The purpose of this study is to determine whether gamma-Hydroxybutyrate (GHB) has prosocial and prosexual effects in healthy male participants, and to characterize these putative effects via behavioral tests, functional magnetic…
- Conditions
- Depressive Disorder, Major, Bipolar Disorder, Autistic Disorder
- Trial name
- NCT02342366
- Testing
- GHB 35 mg/kg p.o., GHB 20 mg/kg p.o.
- Where
- Switzerland
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Stimulant Use, MDMA ('Ecstasy')
Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function
To study the effects of MDMA, compared to a prototypical stimulant, on social motivation, social ability, and neural indices of social function in healthy volunteers
- Conditions
- Stimulant Use, MDMA ('Ecstasy'), Social Behavior, Motivation
- Trial name
- MASM (NCT05379959)
- Testing
- MDMA, Methamphetamine
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Asperger's Disorder, Asperger Disorder
QAIAx (AIhealth4U) - AI Smart Health Cities: Microcity Enclave Program (Quantum AI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360)
BRIEF SUMMARY A. "What is the purpose of this study?" BACKGROUND. The QAIAx clinical trial (Quantum AI/AGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research…
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism
- Trial name
- QAIAx (NCT07661823)
- Testing
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Veterans Recovery Network Inc.
MDMA Discontinuation Syndrome
Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.
The purpose of this study is to measure the effects of MDMA on sleep, mood, thinking, and how your body retains water. The researchers are interested in the effects that occur a few hours after taking MDMA as well as effects…
- Trial name
- 2C (NCT01053403)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- California Pacific Medical Center Research Institute
PTSD, Post Traumatic Stress Disorder, Adolescents
MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents
The primary objective of this study is to determine the safety and feasibility of 3,4-methylenedioxymethamphetamine (MDMA) -assisted psychotherapy to treat resistant post-traumatic stress disorder (PTSD).
- Conditions
- PTSD, Post Traumatic Stress Disorder, Adolescents, Psychotherapy
- Trial name
- NCT06353282
- Testing
- MDMA, Psychotherapy
- Where
- United States
- Sponsor
- University of California, Los Angeles